Quantinno Capital Management LP Sells 269,103 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Quantinno Capital Management LP trimmed its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 80.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 67,424 shares of the company's stock after selling 269,103 shares during the period. Quantinno Capital Management LP's holdings in Maravai LifeSciences were worth $367,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. SG Americas Securities LLC boosted its position in Maravai LifeSciences by 7.3% in the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company's stock valued at $180,000 after buying an additional 2,239 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Maravai LifeSciences by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company's stock worth $164,000 after purchasing an additional 2,851 shares during the last quarter. Performa Ltd US LLC boosted its position in Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock valued at $27,000 after purchasing an additional 4,300 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Maravai LifeSciences by 12.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 70,828 shares of the company's stock worth $387,000 after buying an additional 7,946 shares during the last quarter. Finally, Bleakley Financial Group LLC increased its position in Maravai LifeSciences by 30.1% in the fourth quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company's stock worth $227,000 after buying an additional 9,657 shares during the period. Hedge funds and other institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Stock Performance

MRVI traded down $0.07 during trading on Friday, hitting $2.31. The stock had a trading volume of 202,572 shares, compared to its average volume of 2,332,451. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences Holdings, Inc. has a 12 month low of $1.67 and a 12 month high of $10.03. The company has a 50 day simple moving average of $2.06 and a 200-day simple moving average of $3.75. The firm has a market cap of $586.99 million, a PE ratio of -1.41 and a beta of 0.19.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business's revenue for the quarter was down 26.9% on a year-over-year basis. Analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MRVI. UBS Group dropped their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Robert W. Baird cut their target price on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Morgan Stanley dropped their price target on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. Baird R W downgraded shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Finally, Bank of America reduced their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $6.64.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.